<div id="readability-page-1"><div><p><span>Maetzold Derek J Chief Executive Officer of Castle Biosciences Inc [CSTL] filed a Form 4 on November 26, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><td><span>Date</span></td><td><span>11/25/25</span></td></tr><tr><td><span>Transaction</span></td><td><span>Planned Sale(1)</span></td></tr><tr><td><span>Shares</span></td><td><span>5,115</span></td></tr><tr><td><span>Price</span></td><td><span>$40.05</span></td></tr><tr><td><span>Value</span></td><td><span>$204,851</span></td></tr></tbody></table></div><p><span>Ending Holdings: 307,194 (45,822 - Direct, 261,372 - Indirect)</span></p><ul><li><span>(1)</span></li><li><span>Executed pursuant to a prearranged trading plan (10b5-1).</span></li></ul><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

CSTL

<p>Castle Biosciences Inc's CEO, Derek J. Maetzold, sold 5,115 shares valued at $204,851 as part of a prearranged trading plan. The transaction was disclosed in a Form 4 filing with the SEC on November 26, 2025. Maetzold's remaining holdings are 307,194 shares, with 45,822 held directly and 261,372 indirectly.</p>

CEO Maetzold Sells 5,115 ($204.9K) Of Castle Biosciences Inc [CSTL]